Godrej Consumer Products (GCPL) has delivered consolidated revenue growth of 17.1% year-on-year for Q1FY27, significantly exceeding its full-year guidance of double-digit revenue growth. According to the company's latest quarterly results, the standalone business delivered double-digit revenue growth, supported by high single-digit underlying volume growth (UVG). The company's EBITDA is expected to exceed its double-digit guidance for the quarter, demonstrating strong operational resilience despite near-term margin pressures. As per the company's statement, revenue growth was broad-based across categories and geographies, with the strong performance meaningfully ahead of original expectations. Nuvama Research expects consolidated revenue to expand 17.1% Y-o-Y in Q1FY27, compared with 11% growth in Q4FY26 and 9.9% growth in Q1FY26. Consolidated operating profit could grow by 12.4% Y-o-Y, compared with 10.8% growth in Q4FY26 and a 5% decline Y-o-Y in Q1FY26. JM Financial has maintained a 'Buy' rating on GCPL after the strong Q1 business update, raising its target price to ₹1,250 from ₹1,225, implying an upside of 17% from the previous close of ₹1,076.90.
GCPL has indicated that its operating margins are likely to come under pressure in the first quarter of fiscal year 2027 despite reporting strong revenue growth, as elevated commodity costs weighed on profitability. According to the company's quarterly business update, commodity input costs remained elevated throughout the quarter, leading to margin compression. However, GCPL has taken a price hike of 5% in soaps and household insecticides (HI) and 7% in detergents at the start of FY27, which could translate into an overall price hike of about 3-4%. The consolidated gross margin is anticipated to fall by 80 basis points Y-o-Y to 51.1%, while operating profit margin may decline 77 basis points Y-o-Y to 18.2%. Nuvama Research has retained a 'buy' rating with an unchanged target price of ₹1,505, noting that the company remains confident that it will recover margins through pricing actions, cost savings and media optimisation. Nomura Research expects consolidated EBITDA growth at around 14% year-on-year, in line with the company's indication of "higher than double-digits," also ahead of its full-year guidance.
In India, which contributed 62% of FY26 consolidated sales, revenue growth is expected at 13-14%, supported by high-single-digit volume growth. According to Business Standard, the India business, which accounted for 62% of consolidated sales in FY26, could grow in the 13-14% range with broad-based growth across categories. Nomura Research expects the India business to report around 8% volume growth and 12% revenue growth, supported by stable demand across categories such as home care and personal care. JM Financial expects the India business to report around 8% volume growth and 12% revenue growth, supported by stable demand across categories such as home care and personal care. The brokerage highlighted a stronger-than-expected recovery in the international business, with Indonesia posting "mid-teens revenue growth" led by "double-digit volume growth and market share gains". The company believes "the competitive pressures are abating and the profitability of the business is back" in Indonesia. JM Financial believes building blocks, including portfolio transformation in India, stronger H1 business and improving international business, are in place, with these factors along with a strong start to FY27 and easing inflationary pressures providing comfort on GCPL's ability to achieve its guidance.
The international business segment continues to demonstrate strong performance across multiple markets. According to Business Standard, the international business as a whole is expected to record around 15% revenue growth in Indian rupee terms during the quarter. Indonesia, which accounts for 12% of consolidated sales, saw a strong sequential recovery, with mid-teens revenue growth compared with low single-digit growth in Q4. The international business as a whole is expected to record around 15% revenue growth in Indian rupee terms during the quarter. Godrej Africa, USA and Middle East (GAUM), which accounted for 21% of consolidated sales in FY26, also delivered a strong performance, with volume growth in the teens as the company continues to build FMCG categories. Strong currency tailwinds are expected to drive sales growth in the mid-20% range in GAUM. JM Financial expects strong momentum from the company's Godrej Africa, USA and Middle East (GAUM) business, with "GAUM sales to expand ~20%" indicating broad-based demand across product categories.
GCPL shares surged as much as 4% in early trade on Monday after the company's June quarter business update beat Street expectations. The FMCG stock opened nearly 2% higher at ₹1,095 on the National Stock Exchange (NSE) and climbed to a high of ₹1,118, with shares trading 1% higher at ₹1,088.20 as of 10 AM. Around 1.5 million shares changed hands in the first 45 minutes of trade, according to NSE data, with the stock outperforming the broader markets where the Nifty 50 was up 0.45%. GCPL has underperformed the markets in 2026 so far, falling 12.5% as against a 6.7% decline in the Nifty 50 index, with the stock having slipped 8.7% in one year. Nomura Research expects GCPL to see margin improvement in the coming quarters, with higher investments in new brands and launches expected to aid better revenue growth over the medium term. JM Financial noted that the company's Q1FY27 pre-quarter business update surprised positively on both revenue and operating performance, with the brokerage expecting GCPL to likely see margin improvement in the coming quarters.
